Aduro Biotech (ADRO -2.4%) initiated with Buy rating and $40 (25% upside) price target by BofA Merrill Lynch and an Outperform rating and $48 (50% upside) price target by Leerink Swann.//@淡投:回复@淡投:Roth Capital analyst Joseph Pantginis reiterated a Buy rating and $70 price target on $ADRO(ADRO)$ following the ASCO abstracts.
Pantginis commented, "With the release of the ASCO abstracts, ADRO gives a sneak peak on its progress in the Phase Ib mesothelioma trial. Mesothelin-targeted immunotherapy CRS-207 was found to be well tolerated when combined with chemotherapy and showed anti-tumor activity. We now look for OS and immune response evaluations, which will be presented in a poster on June 1."